TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
14.50
+0.55 (3.94%)
Sep 10, 2024, 1:30 PM CST
-3.01%
Market Cap 10.41B
Revenue (ttm) 149.45M
Net Income (ttm) 235.16M
Shares Out 717.84M
EPS (ttm) 0.32
PE Ratio 45.93
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,644,655
Open 14.10
Previous Close 13.95
Day's Range 14.05 - 14.50
52-Week Range 13.05 - 17.25
Beta 0.77
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About TaiGen Biopharmaceuticals Holdings

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenz... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.